
Opinion|Videos|May 7, 2024
Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO
Author(s)Marion R. Munk, MD, PhD
Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.
Advertisement
Episodes in this series
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Port Delivery System Therapies in Retinal Vascular Diseases
2
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
3
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
4
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
5























